(1.03%) 5 180.74 points
(0.46%) 38 852 points
(1.19%) 16 349 points
(0.32%) $78.73
(-1.23%) $2.17
(0.06%) $2 332.60
(-0.17%) $27.57
(0.65%) $971.15
(0.04%) $0.929
(0.22%) $10.85
(0.05%) $0.796
(-0.01%) $91.34
Live Chart Being Loaded With Signals
PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. The company operates through four divisions: Prescription Pharmaceuticals, Consumer Health, Nutritionals, and Distribution and Logistic...
Stats | |
---|---|
Šios dienos apimtis | 4.63M |
Vidutinė apimtis | 35.28M |
Rinkos kapitalizacija | 67 301.93B |
EPS | IDR0 ( 2024-04-28 ) |
Kita pelno data | ( IDR18.16 ) 2024-08-02 |
Last Dividend | IDR0 ( N/A ) |
Next Dividend | IDR0 ( N/A ) |
P/E | 23.42 |
ATR14 | IDR3.23 (0.22%) |
Tūris Koreliacija
PT Kalbe Farma Tbk. Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
PT Kalbe Farma Tbk. Koreliacija - Valiuta/Žaliavos
PT Kalbe Farma Tbk. Finansinės ataskaitos
Annual | 2023 |
Pajamos: | IDR30 449.13B |
Bruto pelnas: | IDR11 438.05B (37.56 %) |
EPS: | IDR59.81 |
FY | 2023 |
Pajamos: | IDR30 449.13B |
Bruto pelnas: | IDR11 438.05B (37.56 %) |
EPS: | IDR59.81 |
FY | 2022 |
Pajamos: | IDR28 933.50B |
Bruto pelnas: | IDR11 704.07B (40.45 %) |
EPS: | IDR72.71 |
FY | 2021 |
Pajamos: | IDR26 261.19B |
Bruto pelnas: | IDR11 283.78B (42.97 %) |
EPS: | IDR67.92 |
Financial Reports:
No articles found.
PT Kalbe Farma Tbk.
PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. The company operates through four divisions: Prescription Pharmaceuticals, Consumer Health, Nutritionals, and Distribution and Logistic. It offers generic, branded, and licensed drugs, including Brainact, Cefspan, Mycoral, Cernevit, Cravit, Neuralgin, Broadced, Neurotam, Hemapo, and CPG that are distributed to hospitals, pharmacies, and drug stores. The company also provides over-the-counter drugs; energy drinks, ready-to-drink products, supplements, and other preventive products; and nutritional products for infants, toddlers, children, teenagers, adults, pregnant and lactating women, and elders, as well as for consumers with special medical needs. In addition, it offers contract services, including clinical study management, bioavailability/bioequivalence studies, and contract analysis to pharmaceutical companies; and animal health products, as well as operates Mitrasana Clinics, a health care service. Further, the company provides health screening services; operates as an agent and representative for biotechnology products; distributes consumer products, medical equipment, cosmetics, and other trading products; and trades in medical and laboratory equipment and supplies, raw materials for pharmaceutical products, and consumable products for hemodialysis therapy, as well as offers advertising services. PT Kalbe Farma Tbk. was incorporated in 1966 and is headquartered in Jakarta, Indonesia.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.